{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Human+Papillomavirus-18+Positive",
    "query": {
      "condition": "Human Papillomavirus-18 Positive"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 3,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T06:46:44.993Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03603808",
      "title": "VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Anal Intraepithelial Neoplasia",
        "High Grade Squamous Intraepithelial Neoplasia",
        "HIV Positivity",
        "Human Papillomavirus-16 Positive",
        "Human Papillomavirus-18 Positive"
      ],
      "interventions": [
        {
          "name": "Electroporation",
          "type": "DEVICE"
        },
        {
          "name": "HPV DNA Plasmids Therapeutic Vaccine VGX-3100",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "AIDS Malignancy Consortium",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 44,
      "start_date": "2018-09-21",
      "completion_date": "2025-06-17",
      "has_results": true,
      "last_update_posted_date": "2026-05-08",
      "last_synced_at": "2026-05-22T06:46:44.993Z",
      "location_count": 7,
      "location_summary": "San Francisco, California • Atlanta, Georgia • Chicago, Illinois + 4 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03603808"
    },
    {
      "nct_id": "NCT03439085",
      "title": "DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Human Papillomavirus-16 Positive",
        "Human Papillomavirus-18 Positive",
        "Metastatic Malignant Neoplasm",
        "Recurrent Anal Canal Carcinoma",
        "Recurrent Cervical Carcinoma",
        "Recurrent Malignant Neoplasm",
        "Recurrent Penile Carcinoma",
        "Recurrent Vaginal Carcinoma",
        "Recurrent Vulvar Carcinoma",
        "Refractory Malignant Neoplasm",
        "Stage IV Anal Cancer AJCC v8",
        "Stage IV Cervical Cancer AJCC v8",
        "Stage IV Penile Cancer AJCC v8",
        "Stage IV Vaginal Cancer AJCC v8",
        "Stage IV Vulvar Cancer AJCC v8",
        "Stage IVA Cervical Cancer AJCC v8",
        "Stage IVA Vaginal Cancer AJCC v8",
        "Stage IVA Vulvar Cancer AJCC v8",
        "Stage IVB Cervical Cancer AJCC v8",
        "Stage IVB Vaginal Cancer AJCC v8",
        "Stage IVB Vulvar Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Durvalumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 41,
      "start_date": "2018-11-14",
      "completion_date": "2022-09-20",
      "has_results": true,
      "last_update_posted_date": "2024-07-09",
      "last_synced_at": "2026-05-22T06:46:44.993Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03439085"
    },
    {
      "nct_id": "NCT06319963",
      "title": "A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "HPV-Related Cervical Carcinoma",
        "HPV Positive Oropharyngeal Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Two IM injections Lenti-HPV-07",
          "type": "DRUG"
        },
        {
          "name": "One IM injection Lenti-HPV-07",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Theravectys S.A.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 72,
      "start_date": "2024-08-08",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-02-02",
      "last_synced_at": "2026-05-22T06:46:44.993Z",
      "location_count": 4,
      "location_summary": "Orlando, Florida • Tampa, Florida • Tulsa, Oklahoma",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Tulsa",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06319963"
    }
  ]
}